Compare STRIDES PHARMA SCIENCE with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs WYETH LTD - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE WYETH LTD STRIDES PHARMA SCIENCE/
WYETH LTD
 
P/E (TTM) x 14.8 27.7 53.6% View Chart
P/BV x 0.9 5.3 16.4% View Chart
Dividend Yield % 0.6 1.3 43.5%  

Financials

 STRIDES PHARMA SCIENCE   WYETH LTD
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
WYETH LTD
Mar-13
STRIDES PHARMA SCIENCE/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,1471,044 109.8%   
Low Rs642818 78.5%   
Sales per share (Unadj.) Rs317.2298.6 106.3%  
Earnings per share (Unadj.) Rs7.857.2 13.7%  
Cash flow per share (Unadj.) Rs25.158.4 42.9%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.21.8 12.2%  
Book value per share (Unadj.) Rs274.3249.5 109.9%  
Shares outstanding (eoy) m89.5022.72 393.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.1 90.4%   
Avg P/E ratio x114.016.3 700.9%  
P/CF ratio (eoy) x35.715.9 223.9%  
Price / Book Value ratio x3.33.7 87.4%  
Dividend payout %25.529.7 85.8%   
Avg Mkt Cap Rs m80,05821,157 378.4%   
No. of employees `0002.50.5 509.6%   
Total wages/salary Rs m4,341400 1,085.1%   
Avg. sales/employee Rs Th11,325.813,787.4 82.1%   
Avg. wages/employee Rs Th1,731.4813.0 213.0%   
Avg. net profit/employee Rs Th280.12,643.3 10.6%   
INCOME DATA
Net Sales Rs m28,3946,783 418.6%  
Other income Rs m941353 266.8%   
Total revenues Rs m29,3347,136 411.1%   
Gross profit Rs m3,9651,617 245.2%  
Depreciation Rs m1,54027 5,791.0%   
Interest Rs m1,9626 35,680.0%   
Profit before tax Rs m1,4031,938 72.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-5 8,545.1%   
Tax Rs m97632 15.4%   
Profit after tax Rs m7021,301 54.0%  
Gross profit margin %14.023.8 58.6%  
Effective tax rate %6.932.6 21.3%   
Net profit margin %2.519.2 12.9%  
BALANCE SHEET DATA
Current assets Rs m24,8366,984 355.6%   
Current liabilities Rs m18,9932,056 923.8%   
Net working cap to sales %20.672.6 28.3%  
Current ratio x1.33.4 38.5%  
Inventory Days Days7199 71.5%  
Debtors Days Days11324 473.7%  
Net fixed assets Rs m34,289244 14,035.5%   
Share capital Rs m895227 393.9%   
"Free" reserves Rs m23,6515,441 434.7%   
Net worth Rs m24,5465,668 433.1%   
Long term debt Rs m15,51325 62,052.8%   
Total assets Rs m65,4377,901 828.2%  
Interest coverage x1.7353.3 0.5%   
Debt to equity ratio x0.60 14,329.1%  
Sales to assets ratio x0.40.9 50.5%   
Return on assets %4.116.5 24.6%  
Return on equity %2.922.9 12.5%  
Return on capital %6.934.0 20.3%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m15,69715 103,270.4%   
Fx outflow Rs m7352,677 27.5%   
Net fx Rs m14,962-2,662 -562.0%   
CASH FLOW
From Operations Rs m1,871923 202.6%  
From Investments Rs m5,826317 1,838.4%  
From Financial Activity Rs m-10,157-481 2,111.6%  
Net Cashflow Rs m-2,615759 -344.5%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 37.8 11.3 334.5%  
FIIs % 8.6 7.2 119.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 30.4 85.2%  
Shareholders   56,241 21,978 255.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 19, 2019 12:09 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS